Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06282211
Other study ID # CHASE 005
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date February 20, 2024
Est. completion date December 29, 2024

Study information

Verified date February 2024
Source The First Affiliated Hospital of Xinxiang Medical College
Contact Yinghua Ji
Phone 13663030446
Email 54234317@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The name of this prospective study is a multicenter, open-label, randomized controlled clinical study of the efficacy and safety of Ondansetron Oral Soluble Pellicles for the prevention of delayed nausea and vomiting induced by highly emetogenic chemotherapy.


Description:

The aim of this study is to observe the efficacy and safety of ondansetron in delayed nausea and vomiting by its continuous dosing, and it is planned to enroll 184 first-time recipients of highly emetogenic single-day chemotherapy regimens (cisplatin dose 60-75 mg/m2; anthracycline compounds adriamycin ≥ 60 mg/m2 or epothilone ≥ 90 mg/m2 ) who were initiated on a triple combination regimen of fosaprepitant + ondansetron orally soluble film + dexamethasone triple regimen for nausea and vomiting prophylaxis in patients. The primary observation was the incidence and severity of delayed nausea and vomiting in both groups from day 5 after chemotherapy to the second cycle of chemotherapy. The secondary observation indexes include the incidence and severity of delayed nausea in patients in both groups from day 5 after chemotherapy to before the second cycle of chemotherapy; the incidence and severity of anticipatory nausea/vomiting in the second cycle of chemotherapy in both groups; the incidence and severity of nausea/vomiting in patients in both groups on days 1-4 after chemotherapy; and the incidence of adverse events and serious adverse reactions, with a focus on the antiemetic drugs common constipation, headache and other events. This trial was randomized into groups, and the experimental group was preset as group A and the control group as group B. The prevention of nausea and vomiting was carried out with the triple regimen of fosaprepitant (Tanneng, Jiangsu Hausen Pharmaceutical Group Co., Ltd.) + Ondansetron Oral Soluble Pellicles (Aiqisu, Jiangsu Hengrui Pharmaceutical Co., Ltd.) + dexamethasone prior to chemotherapy, and the patients were divided into the treatment group A and the control group B by the use of Ondansetron Oral Soluble Pellicles for continuation of the prophylaxis on the 5-7 days after the chemotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 184
Est. completion date December 29, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years, gender is not limited; 2. Histologically or cytologically confirmed diagnosis of malignant solid tumor; 3. Initial highly emetogenic one-day chemotherapy regimen (cisplatin dose 60-75 mg/m2; anthracycline compound adriamycin = 60 mg/m2 or epothilone = 90 mg/m2 ); and 4. Nausea and vomiting prophylaxis with a triple regimen of fosaprepitant + ondansetron orally dissolved membrane + dexamethasone started before chemotherapy; 5. Expected survival = 3 months; 6. Eastern Cooperative Oncology Group (ECOG) physical status score =2; 7. Patients were able to read, understand, and complete study questionnaires; 8. Patients understood the study procedures and signed a written informed consent form Exclusion Criteria: 1. Patients scheduled to receive multiple days of highly emetogenic chemotherapy within one week; 2. Patients using an antiemetic drug other than the study drug or a drug with an antiemetic active ingredient within 48 h prior to initiation of randomization and/or within one week of enrollment; 3. Symptoms such as vomiting prior to randomization; 4. Patients on opioid therapy (except stable dose administration); 5. Patients treated with a chemotherapy regimen containing generic paclitaxel (using castor oil as a solvent); 6. Patients who have received, or are expected to receive, radiotherapy to the abdomen (including the diaphragmatic plane and below) or pelvis within 1 week before randomization or one week after enrollment; 7. Patients with active infection (e.g., pneumonia) or any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction) other than malignancy; 8. The patient has participated in another clinical trial within the past 4 weeks; 9. Any condition that, in the judgment of the investigator, is unstable or may jeopardize the safety of the subject and his or her compliance with the study; 10. Pregnant or lactating females; 11. Presence of allergic conditions or prior serious adverse reactions to the study drug and excipients; 12. Suffering from psychological, familial, social, or geographic conditions that may prevent compliance with the study protocol and follow-up schedule;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ondansetron Oral Soluble Pellicles
patients applying cisplatin-based chemotherapy regimen were treated with the triple combination of fosaprepitant (Tanneng, Jiangsu Haosen Pharmaceutical Group Co., Ltd.) + Ondansetron Oral Soluble Pellicles (Aiqisu, Jiangsu Hengrui Pharmaceutical Co., Ltd.) + dexamethasone for the prophylaxis of nausea and vomiting prior to the chemotherapy, and were divided into the experimental group and the control group by whether or not to continue the prophylaxis with o Ondansetron Oral Soluble Pellicles for 5-7 days after the chemotherapy as shown in the figure below.

Locations

Country Name City State
China Keya Zhi Weihui None Selected

Sponsors (1)

Lead Sponsor Collaborator
The First Affiliated Hospital of Xinxiang Medical College

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of adverse events and serious adverse reactions throughout the study period Record the incidence of adverse events and serious adverse reactions throughout the study period, focusing on events such as constipation and headache, which are common with antiemetics 21 days
Primary Incidence and severity of delayed vomiting in patients from day 5 after chemotherapy until the second cycle of chemotherapy in both groups The incidence of delayed vomiting was recorded and the severity of delayed vomiting was assessed by the VAS scale. 21 days
Secondary Incidence and severity of delayed nauseating in patients from day 5 after chemotherapy until the second cycle of chemotherapy in both groups The incidence of delayed nauseating was recorded and the severity of delayed nauseating was assessed by the VAS scale. 21 days
Secondary Incidence and severity of nausea/vomiting in patients on days 1-4 after chemotherapy in both groups The incidence of delayed nausea/vomiting was recorded and the severity of delayed nausea/vomiting was assessed by the VAS scale. 4 days
See also
  Status Clinical Trial Phase
Recruiting NCT05016180 - Effect of Ultrasound-guided Transversus Abdominis Plane Block After Laparoscopic Bariatric Surgery Phase 2
Withdrawn NCT00891761 - A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy Phase 3
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT05533281 - Efficacy of Three Antiemetics in Preventing Nausea and Vomiting Phase 4
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Completed NCT00293384 - Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant N/A
Completed NCT00006348 - Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Phase 3
Completed NCT00003817 - Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy Phase 2
Completed NCT00004895 - Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Phase 2
Active, not recruiting NCT06045364 - Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation Phase 1/Phase 2
Completed NCT00978185 - Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy Phase 3
Completed NCT00064272 - UMCCOP 02-01 Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer Phase 2
Completed NCT00003213 - Drugs to Reduce the Side Effects of Chemotherapy Phase 3
Recruiting NCT05690802 - The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV N/A
Recruiting NCT06314906 - Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer Phase 3
Completed NCT00590317 - Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department Phase 2
Completed NCT03185156 - The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate Phase 4
Not yet recruiting NCT06382012 - Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Phase 2/Phase 3
Terminated NCT01275664 - Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer N/A
Completed NCT01590147 - Supportive Intervention Programs Study N/A